ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa Therapeutics announced that CEO Stephen C. Glover will participate in the 2024 BIO International Convention in San Diego from June 3-6, 2024. ZyVersa is developing treatments for renal and inflammatory diseases using two proprietary technologies: the Cholesterol Efflux Mediator™ VAR 200 and the Inflammasome ASC Inhibitor IC 100. The company plans to start a Phase 2a clinical trial for VAR 200 in diabetic kidney disease in the first half of 2024 and is conducting preclinical studies for expanding IC 100's indications to atherosclerosis, obesity, and Parkinson’s disease. An IND filing for IC 100 is expected by year-end, with Phase 1 trials starting in Q1-2025. Glover will be available for one-on-one meetings to discuss these developments.
- CEO Stephen C. Glover will represent the company at a major international event, enhancing visibility.
- Phase 2a clinical trial for VAR 200 in diabetic kidney disease is on track to start in H1 2024.
- Preclinical studies for IC 100 include significant indications like atherosclerosis, obesity, and Parkinson’s disease.
- Near-term readouts expected for IC 100 in atherosclerosis and obesity.
- IND filing for IC 100 expected by end of 2024, with Phase 1 trial to begin in Q1-2025.
- The announcement lacks specific financial data or revenue projections.
- Company still in clinical and preclinical phases, no approved products yet.
- ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of numerous inflammatory diseases.
- Mr. Glover welcomes one-on-one meetings to discuss ZyVersa’s technology, pipeline assets, and key development milestones.
WESTON, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in the 2024 BIO International Convention being held June 3 - 6, 2024 in San Diego, California.
Details for the event are as follows:
| Event: | 2024 BIO International Convention |
| Date: | Monday, June 3 through Thursday June 6, 2024 |
| Location: | San Diego Convention Center |
| Registration: | https://convention.bio.org/registration |
“We are pleased to have the opportunity to meet with our colleagues at the 2024 BIO International Convention as we advance development of our two platform technologies,” stated Mr. Glover. “ZyVersa has made considerable progress in advancing development of our two lead candidates. A Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 is on target to be initiated in the first half of this year in patients with diabetic kidney disease, and preclinical studies for indication expansion are underway with Inflammasome ASC Inhibitor IC 100 for atherosclerosis, obesity, and Parkinson’s disease. Near-term read outs are expected for atherosclerosis and obesity. Likewise, we plan to file an IND for IC 100 by the end of year, and to initiate a Phase 1 trial in Q1-2025. To learn more about our differentiated product pipeline, please schedule a one-on-one meeting through the conference portal.”
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit zyversa.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc. (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.
Corporate, Media, IR Contact
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641
FAQ
What is ZyVersa Therapeutics' stock symbol?
When is ZyVersa's CEO participating in the BIO International Convention?
What are ZyVersa Therapeutics' proprietary technologies?
When will the Phase 2a clinical trial for VAR 200 in diabetic kidney disease start?
What are the planned indications for IC 100?
When is the IND filing for IC 100 expected?
When will the Phase 1 trial for IC 100 begin?
